UNALTERED PHARMACOKINETICS AFTER THE ADMINISTRATION OF HIGH-DOSE ETOPOSIDE WITHOUT PRIOR DILUTION

被引:9
|
作者
EHNINGER, G [1 ]
PROKSCH, B [1 ]
SCHMIDT, H [1 ]
WAIDELICH, P [1 ]
EICHEL, B [1 ]
DOPFER, R [1 ]
机构
[1] UNIV TUBINGEN,KINDERKLIN,W-7400 TUBINGEN 1,GERMANY
关键词
ETOPOSIDE; PHARMACOKINETICS;
D O I
10.1007/BF00685512
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The pharmacokinetics of etoposide following a new method of administration was determined. Undiluted etoposide was given at a dose of 30 mg/kg as part an intensified conditioning regimen prior to bone marrow transplantation. A terminal half-life of 3.4 +/- 0.7 h and a volume of distribution of 15.4 +/- 9.61 were found (n = 8); the AUC was 764 +/- 302-mu-g h ml-1. As compared with those obtained in other pharmacokinetic studies using etoposide diluted in normal saline, our data reflect full systemic bioavailability and unaltered pharmacokinetics. The application of undiluted etoposide makes the therapy easier and less time-consuming and avoids a high fluid volume and a high saline load.
引用
收藏
页码:214 / 216
页数:3
相关论文
共 50 条
  • [1] Pharmacokinetics of etoposide following administration of high-dose etoposide and etoposide phosphate
    Reif, S
    Grimm, J
    Kingreen, D
    Siegert, W
    Schunack, W
    Jaehde, U
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2000, 38 (03) : 156 - 157
  • [2] PHARMACOKINETICS OF HIGH-DOSE ETOPOSIDE
    NEWMAN, EM
    DOROSHOW, JH
    FORMAN, SJ
    BLUME, KG
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (05) : 561 - 564
  • [3] THE PHARMACOKINETICS OF HIGH-DOSE CYCLOPHOSPHAMIDE AND HIGH-DOSE ETOPOSIDE
    CUNNINGHAM, D
    CUMMINGS, J
    BLACKIE, RB
    MCTAGGART, L
    BANHAM, SW
    KAYE, SB
    SOUKOP, M
    MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY, 1988, 5 (02): : 117 - 123
  • [4] SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF HIGH-DOSE ETOPOSIDE
    SCHWINGHAMMER, TL
    JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (12) : 2768 - 2768
  • [5] PHARMACOKINETICS OF HIGH-DOSE ETOPOSIDE AFTER SHORT-TERM INFUSION
    KOHL, P
    KOPPLER, H
    SCHMIDT, L
    FRITSCH, HW
    HOLZ, J
    PFLUGER, KH
    JUNGCLAS, H
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 29 (04) : 316 - 320
  • [6] PHARMACOKINETICS OF AZLOCILLIN AFTER DISCONTINUOUS INTRAVENOUS ADMINISTRATION OF HIGH-DOSE
    NABER, KG
    ADAM, D
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1983, 11 : 115 - 120
  • [7] PHARMACOKINETICS AND PROTEIN-BINDING OF HIGH-DOSE ETOPOSIDE
    SCHWINGHAMMER, TL
    FLEMING, RA
    ROSENFELD, CS
    SHADDUCK, RK
    STEWART, CF
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 49 (02) : 195 - 195
  • [8] PHARMACOKINETICS OF UNDILUTED OR DILUTED HIGH-DOSE ETOPOSIDE WITH OR WITHOUT BUSULFAN ADMINISTERED TO PATIENTS WITH HEMATOLOGIC MALIGNANCIES
    MROSS, K
    BEWERMEIER, P
    KRUGER, W
    STOCKSCHLADER, M
    ZANDER, A
    HOSSFELD, DK
    JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (07) : 1468 - 1474
  • [9] PHARMACOKINETICS OF 2',3'-DIDEOXYCYTIDINE AFTER HIGH-DOSE ADMINISTRATION TO RATS
    IBRAHIM, SS
    BOUDINOT, FD
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1991, 80 (01) : 36 - 38
  • [10] Pharmacokinetics and effects after intravenous administration of high-dose boron to rat
    Teruaki Tagawa
    Koichi Kono
    Tomotaro Dote
    Kan Usuda
    Hiroyuki Nishiura
    Chisato Koizumi
    Masahisa Saito
    Hisangea Nakaya
    Hidehiro Nagaie
    International Archives of Occupational and Environmental Health, 2000, 73 : S98 - S100